Eli Lilly and Company $LLY Stake Lifted by Adams Diversified Equity Fund Inc.

Key Points

• Adams Diversified Equity Fund increased its stake in Eli Lilly by 22.4% in the fourth quarter, buying 9,400 additional shares and bringing its total holding to 51,368 shares valued at about $55.2 million.
• Institutional interest remains strong overall, with hedge funds and other investors owning 82.53% of Eli Lilly’s stock. Several other funds also added to or initiated positions during the same period.
• Analysts remain broadly bullish on the stock: recent price-target hikes and buy ratings leave Eli Lilly with a Moderate Buy consensus and an average target price of $1,227.74.

Adams Diversified Equity Fund Inc. boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 22.4% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 51,368 shares of the company's stock after buying an additional 9,400 shares during the period. Eli Lilly and Company makes up about 1.8% of Adams Diversified Equity Fund Inc.'s investment portfolio, making the stock its 10th largest position. Adams Diversified Equity Fund Inc.'s holdings in Eli Lilly and Company were worth $55,204,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership raised its holdings in Eli Lilly and Company by 67.0% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 167,666 shares of the company's stock valued at $180,187,000 after buying an additional 67,263 shares during the period. Atlas Capital Advisors Inc. purchased a new position in Eli Lilly and Company in the fourth quarter valued at approximately $3,899,000. Ackerman Asset Management LLC purchased a new position in Eli Lilly and Company in the fourth quarter valued at approximately $257,000. Cordoba Advisory Partners LLC purchased a new position in Eli Lilly and Company in the fourth quarter valued at approximately $247,000. Finally, Burton Enright Welch purchased a new position in Eli Lilly and Company in the fourth quarter valued at approximately $2,811,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on LLY. Guggenheim restated a "buy" rating and issued a $1,183.00 price target on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Barclays raised their price target on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an "overweight" rating in a report on Monday, May 4th. Bank of America raised their price target on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a "buy" rating in a report on Tuesday, May 26th. Morgan Stanley restated an "overweight" rating on shares of Eli Lilly and Company in a report on Friday, June 5th. Finally, Cantor Fitzgerald raised their price target on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an "overweight" rating in a report on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,227.74.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and research notes continue to turn more upbeat on Eli Lilly’s earnings outlook, with Erste Group lifting FY2026 and FY2027 EPS estimates and Goldman Sachs reiterating a buy rating on the back of an encouraging obesity-treatment pipeline. Goldman Sachs Maintains a Buy Rating on Eli Lilly (LLY), Cites Encouraging Obesity Treatment Pipeline
• Positive Sentiment: Eli Lilly’s strong growth story is still resonating with investors: recent coverage says the stock is in a buy zone, institutional funds are adding shares, and the company remains a leader in the GLP-1 obesity market after a big earnings beat and raised guidance. Eli Lilly Stock Hits Buy Zone As Earnings Soar 156%. Funds Are Loading Up.
• Positive Sentiment: The company also added a new growth angle by expanding its chronic pain pipeline, including new Phase 2 trials in osteoarthritis and chronic low back pain, which could broaden Lilly’s long-term revenue base beyond obesity and diabetes. Eli Lilly Expands Chronic Pain Pipeline With New Osteoarthritis Trial
• Positive Sentiment: FDA progress for Ebglyss, including an easier once-every-eight-weeks maintenance regimen, adds another commercial catalyst and supports Lilly’s push to diversify into dermatology. FDA Ebglyss Decision Adds New Thread To Eli Lilly Growth Story
• Neutral Sentiment: Lilly also unveiled an AI partnership with Abridge, aimed at speeding drug development, trial enrollment and research; that is strategically positive, but it is a longer-term story than a near-term earnings driver. Eli Lilly’s Abridge Bet Links Healthcare AI To Valuation And Growth
• Negative Sentiment: A key overhang is growing concern that some employers may reduce or drop coverage for GLP-1 weight-loss drugs in 2027, which could pressure demand and reimbursement for Lilly’s obesity franchise. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases 2026-06-11

Eli Lilly and Company Stock Down 2.1%

LLY stock opened at $1,137.01 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,182.73. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $1.07 trillion, a P/E ratio of 40.39, a PEG ratio of 1.24 and a beta of 0.53. The firm has a 50 day simple moving average of $998.47 and a 200-day simple moving average of $1,016.72.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter last year, the company earned $3.34 earnings per share. The business's quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were given a dividend of $1.73 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.